| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Verrica Pharmaceuticals Inc. | Chief Financial Officer | Common Stock | 12,900 | $83,721 | $6.49 | 04 Jun 2021 | Direct |
| Grace Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 10,000 | 08 Jan 2026 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| GRCE | Grace Therapeutics, Inc. | 08 Jan 2026 | 1 | $0 | 4 | Director | 12 Jan 2026, 16:01 |
| GRCE | Grace Therapeutics, Inc. | 09 May 2025 | 1 | $0 | 4 | Director | 13 May 2025, 17:21 |
| GRCE | Acasti Pharma Inc. | 19 Dec 2023 | 1 | $0 | 4 | Director | 20 Dec 2023, 16:06 |
| GRCE | Acasti Pharma Inc. | 10 Oct 2023 | 0 | $0 | 3 | Director | 20 Oct 2023, 12:21 |
| VRCA | Verrica Pharmaceuticals Inc. | 04 Jun 2021 | 1 | +$49,450 | 4 | Chief Financial Officer | 07 Jun 2021, 08:41 |